摘要
目的分析伴有t(8;21)的急性髓系白血病(acute myeloid leukemia,AML)患者CD56表达情况及其预后意义。方法回顾分析我中心33例伴t(8;21)的初诊AML患者的临床特征、治疗疗效及远期预后。结果 CD56阳性与阴性患者在性别、FAB分型、是否伴有附加染色体异常、基因突变、血象、骨髓原始细胞比例及完全缓解率方面均无显著差异(均P>0.05)。CD56阴性患者无复发生存率高于阳性患者,但二者无统计学差异(P=0.273)。CD56阴性患者总生存率明显优于阳性患者(P=0.028)。结论 CD56可能是t(8;21)患者预后不良的指标之一。
Objective To explore the expression and prognostic significance of CD56 in patients with acute myeloid leukemia（AML）with t（8;21）.Methods Thirty-three patients with de novo AML were retrospectively analyzed with regard to clinical characteristics,therapeutic response,and long-term outcome.Results There was no significant difference between patients with and without CD56 expression for gender,FAB subtypes,accompanied with additional chromosome,gene mutations,white blood cell,hemoglobin,platelet,bone marrow blasts,and complete remission rate（all P〉 0.05）.Although the relapse-free survival of patients without CD56 expression was higher than those with,no significant difference was calculated（P=0.273）.However,compared to those with CD56 expression,patients without CD56 expression had superior overall survival（P=0.028）.Conclusion CD56 may be an indicator for unfavorable survival for AML patients with t（8;21）.
出处
《中国实验诊断学》
2016年第3期399-401,共3页
Chinese Journal of Laboratory Diagnosis
